Editas Medicine Q1 Earnings Report Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy EDIT?
Source: seekingalpha
- Earnings Performance: Editas Medicine reported a Q1 GAAP EPS of -$0.26, aligning with expectations, but revenue of $2.8 million fell 39.9% year-over-year and missed estimates by $3.14 million, indicating challenges in revenue growth.
- Cash Flow Status: As of March 31, 2026, Editas had cash and cash equivalents of $123.6 million, down from $146.6 million as of December 31, 2025, reflecting pressure on the company's financial management.
- Market Reaction: Although the Q1 GAAP EPS of -$0.06 beat expectations by $0.20 and revenue of $24.74 million exceeded estimates by $15.97 million, the overall financial performance failed to boost market confidence, potentially affecting future investor trust.
- Industry Outlook: Editas Medicine's ongoing investments and R&D in gene editing, despite current poor financial data, could still lead to business growth and market share increases if effectively translated into market demand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EDIT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EDIT
Wall Street analysts forecast EDIT stock price to rise
7 Analyst Rating
2 Buy
4 Hold
1 Sell
Hold
Current: 2.900
Low
3.00
Averages
3.78
High
4.60
Current: 2.900
Low
3.00
Averages
3.78
High
4.60
About EDIT
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Editas Medicine Q1 Earnings Report Analysis
- Earnings Performance: Editas Medicine reported a Q1 GAAP EPS of -$0.26, aligning with expectations, but revenue of $2.8 million fell 39.9% year-over-year and missed estimates by $3.14 million, indicating challenges in revenue growth.
- Cash Flow Status: As of March 31, 2026, Editas had cash and cash equivalents of $123.6 million, down from $146.6 million as of December 31, 2025, reflecting pressure on the company's financial management.
- Market Reaction: Although the Q1 GAAP EPS of -$0.06 beat expectations by $0.20 and revenue of $24.74 million exceeded estimates by $15.97 million, the overall financial performance failed to boost market confidence, potentially affecting future investor trust.
- Industry Outlook: Editas Medicine's ongoing investments and R&D in gene editing, despite current poor financial data, could still lead to business growth and market share increases if effectively translated into market demand.
See More
Editas Medicine Announces Multiple Conference Presentations
- Conference Presentation Schedule: Editas Medicine will present one oral and two poster presentations at the 2026 ASGCT Annual Meeting, showcasing its latest research in gene editing, thereby reinforcing its leadership position in the gene therapy market.
- EDIT-401 Progress: The company will present preclinical data for EDIT-401, indicating its potential to lower LDL-C, which could provide transformative treatment for hyperlipidemia patients and enhance its competitive edge in the market.
- International Conference Participation: Editas will also deliver oral presentations at TIDES USA 2026 and the 94th EAS Congress, highlighting advancements in CRISPR gene editing technology applications, thus increasing its global influence.
- Commitment to Scientific Communication: The company pledges to publish presentation content on its website during the conferences, ensuring transparency and accessibility of scientific research findings, further promoting the application and development of gene editing technologies.
See More
Editas Medicine Wins CRISPR Patent Dispute Favoring Broad Institute
- Patent Dispute Victory: Editas Medicine has once again triumphed in its long-standing patent dispute with the Broad Institute regarding CRISPR/Cas9 gene editing, as the PTAB ruling reaffirms Broad's inventorship priority, significantly bolstering Editas' patent position and ensuring its competitiveness in the gene editing sector.
- Pipeline Security: Editas holds exclusive licenses to Broad's CRISPR/Cas9 patents, which underpin its pipeline, particularly the experimental therapy EDIT-401 that has demonstrated over 90% reduction in LDL cholesterol in animal studies, positioning it as a potential best-in-class treatment.
- Market Reaction: Despite Editas' stock trading between $0.91 and $4.53 over the past year, closing at $2.32 with a pre-market drop of 4.31%, the company's positive response to the patent ruling may enhance market confidence in the future.
- Portfolio Integrity: Editas emphasizes that its extensive patent portfolio covering both CRISPR/Cas9 and CRISPR/Cas12a technologies remains unaffected by this dispute, providing a solid foundation for advancing gene editing programs aimed at serious diseases and strengthening its strategic position in the biopharmaceutical field.
See More
Editas Medicine Faces Ongoing Decline Risks
- Significant Stock Volatility: Editas Medicine's shares have surged by 80% over the past year, yet the company has lost over 90% of its market value in the last five years, indicating extreme volatility and instability in its stock performance.
- R&D Challenges: Specializing in gene editing, Editas Medicine faces significant commercialization hurdles due to treatment costs exceeding $1 million and complex administration, which undermine investor confidence in its future.
- Project Development Stagnation: The company halted the development of EDIT-101 in 2023 due to the inability to secure a financially robust partner, subsequently abandoning EDIT-103 and reni-cel, highlighting ongoing failures in key projects.
- Slow Clinical Progress: With no programs in late-stage clinical trials and all remaining projects in early development, Editas Medicine faces heightened investment risks, leading to expectations that its stock price may continue to decline over the next five years.
See More
Editas Medicine Q4 Earnings Beat Expectations
- Earnings Highlights: Editas Medicine reported a Q4 GAAP EPS of -$0.06, beating expectations by $0.20, indicating potential improvements in the company's profitability outlook.
- Revenue Performance: Despite total revenue of $24.74 million reflecting a 19.2% year-over-year decline, it exceeded market expectations by $15.97 million, demonstrating the company's resilience in challenging market conditions.
- R&D Revenue Decline: Collaboration and other research and development revenues fell to $24.7 million in Q4 2025 from $30.6 million in the same period of 2024, primarily due to the impact of milestone revenue recognition under the collaboration agreement with BMS.
- Cash Flow Status: As of December 31, 2025, cash and cash equivalents stood at $146.6 million, a significant drop from $269.9 million in 2024, yet the company expects this liquidity to fund operations and capital expenditures through Q3 2027.
See More
Three Genomics Stocks Worth Adding to Your Portfolio
Genomics Overview: Genomics, the study of entire genomes, is gaining traction among pharmaceutical and biotech companies due to advancements in personalized medicine and drug development, distinguishing itself from genetics by focusing on gene interactions and their roles in living systems.
Synthetic Biology and Genome Editing: The field of genomics has led to the rise of synthetic biology and genome-editing technologies like CRISPR/Cas9, which allow for precise DNA modifications to treat genetic diseases, with companies like CRISPR Therapeutics and Intellia Therapeutics at the forefront.
Market Growth Projections: The genomics market is projected to reach $80.17 billion by 2032, while the synthetic biology market is expected to grow at a CAGR of 17.30% from 2025 to 2030, indicating significant investment opportunities in these sectors.
Company Highlights: Notable companies in the genomics space include Editas Medicine, which is developing gene editing therapies, Sana Biotechnology, focusing on cell engineering for diseases like type 1 diabetes, and Pacific Biosciences, known for advanced sequencing technologies, all showing promising stock performance.
See More
Editas Medicine Q1 Earnings Report Analysis
- Earnings Performance: Editas Medicine reported a Q1 GAAP EPS of -$0.26, aligning with expectations, but revenue of $2.8 million fell 39.9% year-over-year and missed estimates by $3.14 million, indicating challenges in revenue growth.
- Cash Flow Status: As of March 31, 2026, Editas had cash and cash equivalents of $123.6 million, down from $146.6 million as of December 31, 2025, reflecting pressure on the company's financial management.
- Market Reaction: Although the Q1 GAAP EPS of -$0.06 beat expectations by $0.20 and revenue of $24.74 million exceeded estimates by $15.97 million, the overall financial performance failed to boost market confidence, potentially affecting future investor trust.
- Industry Outlook: Editas Medicine's ongoing investments and R&D in gene editing, despite current poor financial data, could still lead to business growth and market share increases if effectively translated into market demand.
See More
Editas Medicine Announces Multiple Conference Presentations
- Conference Presentation Schedule: Editas Medicine will present one oral and two poster presentations at the 2026 ASGCT Annual Meeting, showcasing its latest research in gene editing, thereby reinforcing its leadership position in the gene therapy market.
- EDIT-401 Progress: The company will present preclinical data for EDIT-401, indicating its potential to lower LDL-C, which could provide transformative treatment for hyperlipidemia patients and enhance its competitive edge in the market.
- International Conference Participation: Editas will also deliver oral presentations at TIDES USA 2026 and the 94th EAS Congress, highlighting advancements in CRISPR gene editing technology applications, thus increasing its global influence.
- Commitment to Scientific Communication: The company pledges to publish presentation content on its website during the conferences, ensuring transparency and accessibility of scientific research findings, further promoting the application and development of gene editing technologies.
See More
Editas Medicine Wins CRISPR Patent Dispute Favoring Broad Institute
- Patent Dispute Victory: Editas Medicine has once again triumphed in its long-standing patent dispute with the Broad Institute regarding CRISPR/Cas9 gene editing, as the PTAB ruling reaffirms Broad's inventorship priority, significantly bolstering Editas' patent position and ensuring its competitiveness in the gene editing sector.
- Pipeline Security: Editas holds exclusive licenses to Broad's CRISPR/Cas9 patents, which underpin its pipeline, particularly the experimental therapy EDIT-401 that has demonstrated over 90% reduction in LDL cholesterol in animal studies, positioning it as a potential best-in-class treatment.
- Market Reaction: Despite Editas' stock trading between $0.91 and $4.53 over the past year, closing at $2.32 with a pre-market drop of 4.31%, the company's positive response to the patent ruling may enhance market confidence in the future.
- Portfolio Integrity: Editas emphasizes that its extensive patent portfolio covering both CRISPR/Cas9 and CRISPR/Cas12a technologies remains unaffected by this dispute, providing a solid foundation for advancing gene editing programs aimed at serious diseases and strengthening its strategic position in the biopharmaceutical field.
See More
Editas Medicine Faces Ongoing Decline Risks
- Significant Stock Volatility: Editas Medicine's shares have surged by 80% over the past year, yet the company has lost over 90% of its market value in the last five years, indicating extreme volatility and instability in its stock performance.
- R&D Challenges: Specializing in gene editing, Editas Medicine faces significant commercialization hurdles due to treatment costs exceeding $1 million and complex administration, which undermine investor confidence in its future.
- Project Development Stagnation: The company halted the development of EDIT-101 in 2023 due to the inability to secure a financially robust partner, subsequently abandoning EDIT-103 and reni-cel, highlighting ongoing failures in key projects.
- Slow Clinical Progress: With no programs in late-stage clinical trials and all remaining projects in early development, Editas Medicine faces heightened investment risks, leading to expectations that its stock price may continue to decline over the next five years.
See More
Editas Medicine Q4 Earnings Beat Expectations
- Earnings Highlights: Editas Medicine reported a Q4 GAAP EPS of -$0.06, beating expectations by $0.20, indicating potential improvements in the company's profitability outlook.
- Revenue Performance: Despite total revenue of $24.74 million reflecting a 19.2% year-over-year decline, it exceeded market expectations by $15.97 million, demonstrating the company's resilience in challenging market conditions.
- R&D Revenue Decline: Collaboration and other research and development revenues fell to $24.7 million in Q4 2025 from $30.6 million in the same period of 2024, primarily due to the impact of milestone revenue recognition under the collaboration agreement with BMS.
- Cash Flow Status: As of December 31, 2025, cash and cash equivalents stood at $146.6 million, a significant drop from $269.9 million in 2024, yet the company expects this liquidity to fund operations and capital expenditures through Q3 2027.
See More
Three Genomics Stocks Worth Adding to Your Portfolio
Genomics Overview: Genomics, the study of entire genomes, is gaining traction among pharmaceutical and biotech companies due to advancements in personalized medicine and drug development, distinguishing itself from genetics by focusing on gene interactions and their roles in living systems.
Synthetic Biology and Genome Editing: The field of genomics has led to the rise of synthetic biology and genome-editing technologies like CRISPR/Cas9, which allow for precise DNA modifications to treat genetic diseases, with companies like CRISPR Therapeutics and Intellia Therapeutics at the forefront.
Market Growth Projections: The genomics market is projected to reach $80.17 billion by 2032, while the synthetic biology market is expected to grow at a CAGR of 17.30% from 2025 to 2030, indicating significant investment opportunities in these sectors.
Company Highlights: Notable companies in the genomics space include Editas Medicine, which is developing gene editing therapies, Sana Biotechnology, focusing on cell engineering for diseases like type 1 diabetes, and Pacific Biosciences, known for advanced sequencing technologies, all showing promising stock performance.
See More
